MoonLake Immunotherapeutics is set to release results from both the phase 3 VELA-1 and VELA-2 studies in mid-2025. Click here ...

Introduction: The development of nanobodies targeting Programmed Cell Death Protein-1 (PD-1) offers a promising approach in cancer immunotherapy. This study aims to design and characterize a ...

Drugmakers raised the list prices on 575 name-brand drugs in just the first two days of the new year, according to drug price research firm 46brooklyn. Drugs for diabetes, HIV, cancer saw price ...

New nanobody approach shows early promise against ... for which there are two U.S. approved human antibody drugs - Ebanga from Ridgeback Biotherapeutics and Inmazeb from Regeneron Pharmaceuticals ...

To address this challenge, researchers at the University of Minnesota and the Midwest Antiviral Drug Discovery (AViDD) Center have developed the first nanobody-based inhibitors targeting the Ebola ...